A novel ventricular restraint device (ASD) repetitively deliver Salvia miltiorrhiza to epicardium have good curative effects in heart failure management

作者:Naveed Muhammad; Li Wenhua; Gang Wang; Mohammad Imran Shair; Abbas Muhammad; Liao Xiaoqian; Yang Mengqi; Zhang Li; Liu Xiaolin; Qi Xiaoming; Chen Yineng; Lv Jiadi; Ye Linlan; Wang Zhijie*; Ding Chen Ding*; Feng Yu*; Zhou Xiaohui*
来源:Biomedicine & Pharmacotherapy, 2017, 95: 701-710.
DOI:10.1016/j.biopha.2017.07.0126

摘要

A novel ventricular restraint is the non-transplant surgical option for the management of an end-stage dilated heart failure (HF). To expand the therapeutic techniques we design a novel ventricular restraint device (ASD) which has the ability to deliver a therapeutic drug directly to the heart. We deliver a Traditional Chinese Medicine (TCM) Salvia miltiorrhiza (Danshen Zhusheye) through active hydraulic ventricular support drug delivery system (ASD) and we hypothesize that it will show better results in HF management than the restraint device and drug alone. SD rats were selected and divided into five groups (n = 6), Normal, HF, HF + SM (IV), HF + ASD, HF + ASD + SM groups respectively. Post myocardial infarction (MI), electrocardiography (ECG) showed abnormal heart function in all groups and HF + ASD + SM group showed a significant therapeutic improvement with respect to other treatment HF, HF + ASD, and HF + SM (IV) groups on day 30. The mechanical functions of the heart such as heart rate, LVEDP, and LVSP were brought to normal when treated with ASD + SM and show significant (P value < 0.01) compared to other groups. BNP significantly declines in HF + ASD + SM group animals compared with other treatment groups. Masson's Trichrome staining was used to study histopathology of cardiac myocytes and quantification of fibrosis was assessed. The large blue fibrotic area was observed in HF, HF + ASD, and HF + SM (IV) groups while HF + ASD + SM showed negligible fibrotic myocyte at the end of study period (30 days). This study proves that novel ASD device augments the therapeutic effect of the drug and delivers Salvia miltiorrhiza to the cardiomyocytes significantly as well as provides additional support to the dilated ventricle by the heart failure.